BREZTRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

FOR PATIENTS WITH COPD,
CHOOSE BREZTRI1-3

BREZTRI is not indicated for the relief of acute bronchospasm or for the treatment of asthma.

BREZTRI significantly reduced the annual rate of moderate or severe COPD exacerbations vs LAMA/LABA (RR=0.76; P<0.0001) and ICS/LABA (RR=0.87; P=0.0027) in a 52-week study.1,2†

Annual rate estimate: BREZTRI 1.08; LAMA/LABA 1.42; ICS/LABA 1.24.1,2

In a 52-week study in patients with ≥1 exacerbation within the last year,

THE ONLY TRIPLE THERAPY VS ICS/LABA TO SHOW A SIGNIFICANT REDUCTION IN COPD HOSPITALIZATIONS2,4,5*

*Hospitalization for a severe COPD exacerbation.

20% Reduction in COPD Hospitalization
20% Reduction in COPD Hospitalization

REDUCTION VS ICS/LABA2,4

(rate ratio=0.80; P=0.02)

STUDY 1

Reduction in severe exacerbations2

16% reduction vs LAMA/LABA (rate ratio=0.84; P=0.09)2

Annual rate estimate: BREZTRI 0.13; ICS/LABA 0.16; LAMA/LABA 0.15.2

Significant reduction in moderate or severe exacerbations

24% reduction vs LAMA/LABA (rate ratio=0.76; P<0.0001)

13% reduction vs ICS/LABA (rate ratio=0.87; P=0.0027)

Annual rate estimate: BREZTRI 1.08; LAMA/LABA 1.42; ICS/LABA 1.24.

Study 1: Patients (N=8588) with ≥1 moderate or severe exacerbation(s) in the year prior to screening.

BREZTRI is administered as 2 inhalations twice daily.

Fixed-dose combination: ICS/LAMA/LABA.

§Based on predefined Type-1 error control plan.

RR=rate ratio.

BREZTRI IS THE ONLY TRIPLE THERAPY THAT CONTAINS BUDESONIDE1,5

Fixed-dose combination:  ICS/LAMA/LABA.

ICS/LAMA/LABA.

In a 24-week study, BREZTRI demonstrated a significant improvement in FEV1 AUC0-4 vs ICS/LABA (116 mL; P<0.0001) and an improvement in change from baseline in morning pre-dose trough FEV1 vs LAMA/LABA (13 mL; P=0.2375) at Week 24.1,3

In a 24-week study where the majority of patients did not have a history of exacerbations within the last year,3*

THE ONLY TRIPLE THERAPY VS LAMA/LABA TO PREVENT MODERATE OR SEVERE EXACERBATIONS1,3,5

52% Reduction in Exacerbation
52% Reduction in Exacerbation

REDUCTION VS LAMA/LABA1,3

(rate ratio=0.48; unadjusted P<0.0001)1,3‡

STUDY 2

Reduction in moderate or severe exacerbations1,3

18% reduction vs ICS/LABA (rate ratio=0.82; P=0.2792)1,3

Annual rate estimate: BREZTRI 0.46; ICS/LABA 0.56; LAMA/LABA 0.95.3

Difference in severe exacerbations§,6 (other endpoint)7

BREZTRI vs LAMA/LABA (rate ratio=0.36; 95% CI: 0.18, 0.70)

BREZTRI vs ICS/LABA (rate ratio=0.85; 95% CI: 0.34, 2.13)

Annual rate estimate: BREZTRI 0.047; ICS/LABA 0.055; LAMA/LABA 0.131.

*Study 2: Patients (N=1896) were not required to have a history of moderate or severe exacerbations in the year prior to screening.

BREZTRI is administered as 2 inhalations twice daily.

Fixed-dose combination: ICS/LAMA/LABA.

P value is considered unadjusted due to nonsignificant results higher in the testing hierarchy.

§Results are descriptive only.

BREZTRI IS THE ONLY TRIPLE THERAPY THAT CONTAINS BUDESONIDE1,5

Fixed-dose combination:  ICS/LAMA/LABA.

ICS/LAMA/LABA.